TP53 and adenocarcinoma: The analysis of the TFAP2A gene expression level in relation to the abovementioned clinical and demographic characteristics among adenocarcinoma patients (Figure 4A) showed a statistically significant difference only in the context of TP53 status (p < 0.001).